NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum
2024年7月17日 - 8:00PM
NGM Biopharmaceuticals, Inc. (NGM Bio), a privately held
biotechnology company focused on discovering and developing
transformative therapeutics for patients, today announced a $122
million Series A financing led by TCG with participation from a
select group of investors. NGM Bio will use the proceeds from the
Series A financing to initiate a planned registrational trial of
aldafermin, an engineered FGF19 analog, for the treatment of PSC,
and to complete a planned Phase 2 trial of NGM120, a GDF15/GFRAL
antagonist, for the treatment of HG. Both trials are expected to
begin in the fourth quarter of 2024.
“At the beginning of this year, we unveiled our strategy to
advance clinical development efforts for two serious, rare
conditions characterized by significant unmet patient need. This
Series A capital strengthens our financial position, enabling us to
progress our planned registrational trial of aldafermin in primary
sclerosing cholangitis and to evaluate NGM120 in a proof-of-concept
study for hyperemesis gravidarum,” said David J. Woodhouse, PhD,
Chief Executive Officer at NGM Bio. “Having just completed a
take-private transaction in April to bolster our efficiency and
flexibility as a company, we’re grateful to TCG and our new
investors for their support of these important programs, and we
look forward to sharing more details on both trials in the coming
months.”
“The Column Group has long championed NGM’s mission to turn
extraordinary scientific discoveries into meaningful therapeutics.
NGM continues to show remarkable resilience and persistence in its
pursuit of life-saving medicines while maintaining the highest
level of scientific rigor. With this Series A investment, TCG is
delighted to extend our investment in NGM and support the
compelling opportunities presented by aldafermin and NGM120 as
potential treatments for PSC and HG, respectively,” said Peter
Svennilson, Founder and Managing Partner of TCG. Concurrent with
the Series A financing, Mr. Svennilson joined NGM Bio’s Board of
Directors.
Aldafermin as a Potential Treatment for PSC
PSC is a rare disease that irreparably damages the bile ducts,
leading to bile acid dysregulation, which ultimately can result in
end-stage liver disease, liver failure and bile duct
cancer. NGM Bio’s advancement of aldafermin as a potential
treatment for PSC is based on a large body of clinical data that
supports its differentiated potential to address the bile acid
dysregulation underpinning the disease, including NGM Bio’s prior
Phase 2 study in PSC. NGM Bio anticipates that the registrational
trial for aldafermin in PSC will utilize proposed surrogate
endpoints with the goal of obtaining accelerated approval.
Learn more about aldafermin as a potential treatment for PSC
here.
NGM120 as a Potential Treatment for HG
HG is characterized by intractable nausea and vomiting (as
frequent as 10 to 15 times per day), which results in dehydration,
debility, weight loss and malnutrition. HG has a significant
physical and psychosocial impact on patients and leads to overall
higher rates of fetal loss and termination, preeclampsia, preterm
birth, low birth weight, fetal malnutrition, maternal depression,
and in some cases, suicidal thoughts. This condition is the second
leading cause of hospitalization in pregnancy (second to preterm
labor) and typically recurs in subsequent pregnancies.
Development of NGM120 as a potential treatment for HG is rooted
in NGM Bio’s decade-long efforts to advance the understanding of
GDF15 biology and explore its therapeutic application in a number
of disease areas. Recent genetic research confirms the link between
HG and higher serum levels of GDF15. NGM120 is an antibody designed
to block GDF15 signaling through its cognate receptor, GFRAL, in
cells at the base of the brain involved in triggering nausea and
vomiting and, thereby, may have therapeutic benefit for treating
patients suffering from HG.
Learn more about NGM120 as a potential treatment for HG
here.
Aldafermin and NGM120 were both discovered through NGM Bio’s
in-house discovery engine.
Abbreviations (in alphabetical order)
FGF19 = fibroblast growth factor 19; GDF15 = growth
differentiation factor 15; GFRAL = glial cell-derived neurotrophic
factor receptor alpha-like
About NGM Bio
NGM Biopharmaceuticals, Inc. (NGM Bio), a wholly owned
subsidiary of NGM Bio Holdings, Inc., a privately held
biotechnology company, is focused on discovering and developing
novel, life-changing medicines for people whose health and lives
have been disrupted by disease. NGM Bio’s biology-centric drug
discovery approach aims to seamlessly integrate interrogation of
complex disease-associated biology and protein engineering
expertise to unlock proprietary insights that are leveraged to
generate promising product candidates, enable their rapid
advancement into proof-of-concept studies and address high unmet
patient need. Visit us at http://www.ngmbio.com for more
information.
Media
Contact: Liz
Meloneliz@melonecomm.com
OR
media@ngmbio.com